Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant depression (TRD). This application marks a significant milestone in the treatment of major depressive disorder (MDD). The American pharma major has submitted a supplemental New Drug Application (sNDA) to the […]